Adagio Medical Treats First Atrial Fibrillation Patients Using New One Shot+(TM) Cryoablation Catheter

Simplified Procedure for Achieving Pulmonary Vein Isolation (PVI) with a Single Continuous Transmural Lesion

LAGUNA HILLS, California, Oct. 1, 2018 /PRNewswire/ -- Adagio Medical, Inc., the developer of the iCLAS(TM) technology, the company's ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces that the first patients were successfully treated with its new One Shot+(TM) cryoablation catheter. The new catheter is aimed at simplifying the ablation procedure for achieving pulmonary vein isolation (PVI) as well as other continuous ablation lesions of non-PV targets in the treatment of patients with atrial fibrillation.

The iCLAS(TM) procedure with the One Shot+ catheter uses a single transseptal approach and intuitive, anatomical navigation, allowing the clinician to quickly and safely create continuous and focal transmural lesions in the left and right atrium. This catheter incorporates diagnostic electrodes that facilitate navigation of the catheter to the ablation site and also provides real-time monitoring of electrograms to confirm successful lesion creation. To date, Adagio's ultra-low temperature cryoablation technology has successfully treated more than 50 arrhythmia patients enrolled in ongoing multi-center European studies.

The new One Shot+ cryoablation catheter has been used to create continuous and focal transmural lesions throughout the atrial endocardium including the pulmonary vein antrum, posterior wall, mitral isthmus, cavo-tricuspid isthmus, and identified targeted drivers.

"This technology allows me to provide a very efficient treatment to my patients," says Dr. Tom de Potter, MD, FEHRA, Associate Director, Cardiovascular Center Department of Cardiology, Electrophysiology Section at OLV Hospital, in Aalst, Belgium. "I am very pleased to see that with this latest generation of Adagio's cryoablation catheter, I can achieve complete PVI considerably faster than with other treatment modalities with unsurpassed efficacy. The new adjustable diagnostic capacity simplifies the procedure and makes it much less operator-dependent. I am looking forward to performing more cases with this device."

"Adagio has been developing the ultra-low temperature cryoablation technology for nearly seven years and has proven that it produces very promising clinical outcomes," says Olav Bergheim, CEO of Adagio Medical. "Lately, our focus has been on making this technology even more physician friendly and easier to use, while maintaining its superior clinical capabilities. The new One Shot+ catheter was designed to enable the clinician to isolate all pulmonary veins with continuous transmural lesions in under 20 minutes of total dwell time. We're very pleased that this goal has already been realized in several of these cases."

About Adagio Medical

Adagio Medical, Inc. (www.adagiomedical.com [http://www.adagiomedical.com/]) is a privately held company located in Laguna Hills, California developing innovative cryoablation technologies that create continuous, linear, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter and ventricular tachycardia. Adagio Medical, Inc. is a Fjord Ventures portfolio company. For additional information please send an email to info@adagiomedical.com [mailto:info@adagiomedical.com].

CONTACT: Hakon Bergheim, hbergheim@adagiomedical.com

Web site: https://www.adagiomedical.com/

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234